Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment

Br J Dermatol. 2023 Aug 24;189(3):339-341. doi: 10.1093/bjd/ljad149.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Interleukin-13
  • Pemphigoid, Bullous* / chemically induced
  • Pemphigoid, Bullous* / drug therapy

Substances

  • dupilumab
  • Interleukin-13
  • Immune Checkpoint Inhibitors
  • Antibodies, Monoclonal, Humanized